FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck CancerBenzinga • 06/11/19
Merck to buy cancer-treatment biotech Tilos Therapeutics for up to $773 millionMarket Watch • 06/10/19
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster HeadacheZacks Investment Research • 06/07/19
Merck Makes Case For Keytruda In Lung Cancer After Latest Long-Term Survival DataSeeking Alpha • 06/04/19